AstraZeneca Urges Fed. Circ. To Rethink IP Ruling For Mylan
By Adam Lidgett ( January 25, 2022, 4:31 PM EST) -- AstraZeneca wants the Federal Circuit to rethink a split panel decision that gave Mylan another chance to try to show that its planned generic of inhaler asthma treatment Symbicort doesn't infringe a trio of patents on the product....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.